Multicenter Registry Analysis of Bivalirudin for Primary Anticoagulation in Pediatric HeartMate 3 Recipients: ACTION Analysis

ASAIO Journal 2026

View at publisher
Authors: Áine Lynch, Muhammad Farrukh Shezad, Benjamin Kroslowitz, Aamir Jeewa, John C. Dykes, Sabrina Law, Matthew O’Connor, Ryan J. Butts, Anna Joong, Angela Lorts, Shahnawaz M. Amdani, Christina J. VanderPluym
DOI: 10.1097/mat.0000000000002692
Cited by: 0
References: 17

Abstract

Bivalirudin, a direct thrombin inhibitor, is increasingly used as an alternative to heparin in pediatric mechanical circulatory support (MCS) and has resulted in improved stroke-free survival in children supported by paracorporeal pulsatile devices. However, for those supported by implanted continuous-flow devices, such as HeartMate 3, significant practice variation exists in agents used as early intravenous anticoagulation. Leveraging ACTION VAD registry data, we sought to compare early hemocompatibility-related adverse events (

Fields of Study & Subjects

Mechanical Circulatory Support Devices Heparin-Induced Thrombocytopenia and Thrombosis Transplantation: Methods and Outcomes

Publication details

Journal / source
ASAIO Journal
Publication date
12 March 2026
Language
EN